How Ozempic Affects Anxiety and Depression: A Psychiatric Clinician Explains

Ozempic is a brand name for semaglutide, a GLP-1 receptor agonist, a type of medication that mimics a gut hormone to help regulate blood sugar and appetite. It became a household name as one of the first drugs in this class to take off, so its name is often used as shorthand for the whole category, which also includes Wegovy (the same active ingredient, for weight loss) and closely related medications like tirzepatide (Mounjaro and Zepbound). The focus here is Ozempic, but the questions about mood and anxiety apply across GLP-1 medications as a group.

The reason these drugs can affect mood at all is that GLP-1 receptors are not only in the gut; they are also active in brain regions involved in reward, stress, and emotional regulation. That brain activity is thought to underlie the steadier mood and reduced cravings many people report. The flip side is that some people describe a dampened or muted emotional state, while others feel relief as the stress of weight and blood-sugar management eases.

The clearest evidence so far comes from large drug-safety databases that collect reports of side effects from millions of people. One multinational VigiBase study reviewed more than two million of these reports and found a statistical link between semaglutide and anxiety. A separate community study of more than 162,000 matched individuals with obesity, published in Scientific Reports, found that people prescribed GLP-1 medications had a 108% higher rate of anxiety than similar people who were not, along with higher rates of depression.

It is important to read these numbers carefully. They show that anxiety is being reported more often among people on these drugs, not that the medication definitely causes it. People who pursue GLP-1 treatment often already have higher baseline rates of anxiety, depression, and disordered eating, which makes cause and effect hard to untangle. Rapid weight loss, a changing body image, and the drug's physical side effects can all stir anxiety on their own, separate from any direct effect on the brain. For anyone with a history of disordered eating, the appetite suppression itself is worth extra caution, an issue explored further in the relationship between Ozempic and eating disorders. Still, the signal is strong enough that clinicians take it seriously when someone develops new or worsening anxiety after starting the medication.

Anxiety often comes with low mood, so it makes sense that people also ask whether Ozempic can cause depression. The same large safety database that flagged anxiety actually showed an even stronger pattern for depression and low mood. There are also individual cases where someone developed serious mental health symptoms within a few weeks of starting semaglutide, and those symptoms faded once they stopped the medication. This is not just an Ozempic issue. Tirzepatide (sold as Mounjaro and Zepbound) and other drugs in the same family have led to similar reports of anxiety and mood changes.

The news is not all bad, though. A systematic review of GLP-1 agonists for psychiatric symptoms found that in one small study, liraglutide was associated with improvements in depression and the ability to experience pleasure, while results in people with type 2 diabetes were mixed. Other studies found no real change either way. In short, people respond differently: some feel better, most feel about the same, and a smaller group feels worse, and there is no reliable way yet to tell ahead of time who will react which way. If you are already living with depression, it is worth telling your provider about any new mental health symptoms right away.

Most of what is known about GLP-1 long-term effects centers on physical outcomes such as gastrointestinal symptoms, gallbladder issues, and muscle loss, because these medications are still relatively new in widespread non-diabetic use. The psychiatric long-term picture is thinner. A real-world FAERS pharmacovigilance analysis noted that early clinical trials did not show a clear link between GLP-1 use and psychiatric adverse events, even as later post-marketing reports raised flags. That gap between controlled trials and real-world reporting is exactly why ongoing monitoring matters.

Regulatory reviews to date have not found evidence of psychiatric harm at the population level. After investigating reports of suicidal thoughts, the European Medicines Agency concluded that available evidence does not support a causal association between GLP-1 receptor agonists and suicidal or self-injurious thoughts. United States regulators reached the same conclusion. Long-term vigilance continues, but the regulatory consensus is that these drugs are not driving a hidden epidemic of psychiatric harm.

Anyone starting or already taking a GLP-1 medication should treat persistent mood changes as a reason to check in with a provider, not something to wait out. Warning signs worth raising promptly include new or worsening anxiety, a flat or numb emotional state, loss of interest in things that once brought pleasure, and any thoughts of self-harm. None of these should be dismissed as part of weight loss.

Encouragingly, the same population-level data that tempers alarm also points toward safety: an NIH-funded Nature Medicine study found that people treated with semaglutide had a 49% to 73% lower risk of suicidal ideation than those on other obesity or diabetes medications. For most people, GLP-1 treatment will not destabilize their mental health, but for the minority who notice a change, professional support can make a difference. Coordinating care between a provider and a mental health clinician helps weigh the metabolic benefits against any psychiatric cost, and lets treatment for anxiety run alongside, rather than against, the medication.

The honest answer is that we don't have a final answer yet. Safety reports and some larger studies have raised a possible link between Ozempic and anxiety, but the agencies that regulate these drugs have not found proof that the medication actually causes it. In everyday terms, this means there is no one-size-fits-all answer, and your care should fit you. If you have a history of anxiety, depression, or other mental health concerns, it is worth checking in with your provider more often while on the medication. And if you notice your mood shifting, you deserve a clinician who listens and takes it seriously, rather than chalking everything up to weight loss.

At LifeStance, our outcomes data report shows that 79% of individuals experienced clinically significant improvement in anxiety symptoms and 73% in depression symptoms*, a reminder that support is available and these conditions are treatable.

GLP-1 medications should only be taken as prescribed by a qualified clinician. Individual experiences vary, and these medications may not be appropriate for everyone.

*amongst 140,000 LifeStance patients with at least moderate anxiety and 150,000 with at least moderate depression